NYSE · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · LARGE CAP
Charles River Laboratories International, Inc. CRL
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$4.0B
▼ 0.9% vs FY2024
EPS · FY25
$-2.91
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-4.4%
Net margin · FY25
-3.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 4.0B
Revenue, FY2025 · full 18-year series below
Revenue
Net income
The company lost 4 cents on every revenue dollar this year.
Per share
USD -2.91
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-4.4%
Return on equity, FY2025
ROE
Operating margin0.6%
Net margin-3.6%
Return on assets-2.0%
Each USD of equity lost 4 cents this year.
Returned to shareholders
USD 360.0M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 360.0M
Share of profit-249.4%
Consecutive raises—
USD 360.0M in buybacks went back to shareholders in a year without profit.
Growth
+6.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.3%
+6.5%
+11.4%
+8.8%
Returned to shareholders
+198.4%
+16.5%
+0.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years−1.1%
Change, 10 years+5.4%
The share count shrank 1% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 7.1B
total assets, end of FY2025
Total assetsUSD 7.1B
EquityUSD 3.2B
CashUSD 213.8M
Gross debtUSD 2.1B
Net debtUSD 1.9B
Current ratio1.29×
Net debt stands at 61% of equity.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
4.0
4.0
4.1
4.0
3.5
2.9
2.6
2.3
1.9
1.7
1.4
1.3
1.2
1.1
1.1
1.1
1.2
1.3
Operating income $B
0.0
0.2
0.6
0.7
0.6
0.4
0.4
0.3
0.3
0.2
0.2
0.2
0.2
0.2
0.2
−0.3
0.2
−0.5
EBITDA $B
0.4
0.6
0.9
1.0
0.9
0.7
0.5
0.5
0.4
0.4
0.3
0.3
0.2
0.2
0.3
−0.2
0.3
−0.4
Income tax $B
0.0
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.2
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.1
Net income $B
−0.1
0.0
0.5
0.5
0.4
0.4
0.3
0.2
0.1
0.2
0.1
0.1
0.1
0.1
0.1
−0.3
0.1
−0.5
EPS, diluted $
−2.91
0.20
9.22
9.48
7.60
7.20
5.07
4.62
2.54
3.23
3.13
2.66
2.12
2.01
2.14
−5.38
1.74
−7.80
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−4.4
0.6
14.4
17.6
16.8
19.4
17.1
19.2
13.1
19.7
21.3
19.3
16.6
17.4
18.1
−33.2
8.2
·
Shares out B
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
·
0.05
0.06
0.07
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
51 of 51
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed